作者: Yantao He , Xing Guo , Zhi-Hong Yu , Li Wu , Andrea M. Gunawan
DOI: 10.1016/J.BMC.2015.03.066
关键词:
摘要: Abstract The ubiquitin-like domain-containing C-terminal domain phosphatase 1 (UBLCP1) has been implicated as a negative regulator of the proteasome, key mediator in ubiquitin-dependent protein degradation. Small molecule inhibitors that block UBLCP1 activity would be valuable research tools and potential therapeutics for human diseases caused by cellular accumulation misfold/damaged proteins. We report salicylic acid fragment-based library approach aimed at targeting both active site its adjacent binding pocket enhanced affinity selectivity. Screening focused libraries led to identification first potent selective inhibitor 13. Compound 13 exhibits an IC50 1.0 μM greater than 5-fold selectivity against large panel phosphatases from several distinct families. Importantly, possesses efficacious is capable inhibiting function cells, which turn up-regulates nuclear proteasome activity. These studies set groundwork further developing compound into chemical probes or therapeutic agents phosphatase.